MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients
Not Applicable
Completed
- Conditions
- Prostate Cancer
- Registration Number
- NCT00165386
- Lead Sponsor
- Dana-Farber Cancer Institute
- Brief Summary
The purpose of this study is to target lesions of the prostate in the bone and to biopsy these lesions using MRI to identify the areas.
- Detailed Description
* This study involves a one-time, MRI-guided bone marrow biopsy. Prior to this procedure, patients will need to have a bone scan performed within the last three months and a PSA blood test drawn within one month of registration to the study.
* Patients are also required to participate in the DFCI research study "Collection of Specimens and Clinical Data for Patients with Prostate Cancer or at High Risk for Prostate Cancer".
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
- Histologic diagnosis of prostate cancer
- Bone scan consistent with or suspicious of metastatic prostate cancer within last three months
- Platelet count > 50,000/ul
- PT and aPTT < 1.5 x control
- At least one week removed from taking aspirin or coumadin
- Currently participating in protocol "Collection of Specimens and Clinical Data for Patients with Prostate Cancer or at High Risk for Prostate Cancer"
Read More
Exclusion Criteria
- Devices incompatible to MR studies (e.g. pacemakers, ear implants, etc.)
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To compare the yield of detecting metastatic prostate cancer tissue using MRI-guided bone marrow needle biopsies to that of historical controls obtained through unguided biopsies.
- Secondary Outcome Measures
Name Time Method To evaluate the sensitivity of radiographic bone marrow changes detected by MRI for prostate cancer, as determined by the pathologic findings from bone marrow biopsy.
Trial Locations
- Locations (1)
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States